Applications for a phase III clinical trial of microcore biosioroni therapy SCLC Critical III. were accepted

Small cell lung cancer accounts for about 15-20% of lung cancer.
compared with non-small cell lung cancer, small cell lung cancer lack of clear tumor-driven genes and the corresponding targeted treatment drugs, clinical chemotherapy-based, although short-term efficacy but easy to relapse, the long-term survival of patients far worse than non-small cell lung cancer, clinically urgent need for new mechanisms of treatment drugs.
is a new chemical structure with global patent protection designed and developed by Microcore Bio, which is a multi-target multi-path selective kinase inhibitor.
Theo Ronnie selectively inhibits aurora B, CSF1R and VEGFR/PDGFR/c-Kit and other kinase targets, thereby inhibiting tumor cell proliferation, enhancing anti-tumor immunity and inhibiting tumor angiogenesy, achieving multi-pathentic mechanism of anti-tumor effect, with better animal drug activity and good safety than similar mechanism drugs.
by inhibiting the molecular mechanisms associated with the Aurora B pathland of small cell lung cancer, there is a basis for the efficacy of single-drug treatment of SCLC, which is also an important marker of Theuroni's differentiation from other anti-angiogenesic therapist drugs.
trials, SCLC patients with failed multi-line therapy achieved very positive results in single-drug therapy compared to historical control data.
As an original innovative drug that treats major diseases that pose a serious threat to life and health and has a clear clinical advantage over existing treatments, Theroni's adaptation to small cell lung cancer was included in the "breakthrough treatment variety" by CDE on December 25 last year.
The clinical trial, a key Phase III, randomized, double-blind multi-center study aimed at confirming the effectiveness and safety of Theuroni's single drug for treating small cell lung cancer that progresses or relapses after a two-line chemotherapy regimen, is led by Professor Shi Yuankai of the Cancer Hospital of the Chinese Academy of Medical Sciences. Dr. Lu Xianping, founder, chairman and general manager of
Microcore Bio, said, "The inclusion of Theo Ronnie in the 'breakthrough therapeutic varieties' and Phase III. phase clinical trials has been accepted, which fully reflects the importance and efficient execution of innovative drugs by China's regulatory authorities, and also lays a good start for phase III.
we will start Phase III.III clinical trials of Theoroni's treatment of SCLC as soon as possible, and believe that Theroni's unique and new mechanism of action will provide more new treatment options for clinically needed oncology patients in the future.
" At the same time, Microcore Bio has completed a number of single-drug or combined treatment phase II clinical trials in China for ovarian cancer, small cell lung cancer, non-Hodgkin's lymphoma, liver cancer, etc., demonstrating positive clinical efficacy and good human safety tolerance.
, Theuroni has applied for more than 40 invention patents worldwide, and his research and development has been supported by a number of national, provincial and municipal scientific research projects.
note: There are deletions in the original text